Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.; Agreement Allows Premier Members, At Their Discretion, To Take Advantage Of Special Pricing And Terms Pre-negotiated By Premier For EXPAREL
Portfolio Pulse from Benzinga Newsdesk
Pacira BioSciences, Inc. (NASDAQ:PCRX) has entered into a national group purchasing agreement with Premier, Inc. for its non-opioid pain management solution, EXPAREL. This agreement, effective January 1, 2024, allows Premier members to access special pricing and terms for EXPAREL, aiming to improve patient care and reduce healthcare costs. The collaboration aligns with both companies' goals of advancing innovation and patient safety while expanding Pacira's reach in the U.S. healthcare market.
February 07, 2024 | 1:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pacira BioSciences' partnership with Premier, Inc. for EXPAREL is expected to expand its market reach and support its mission of non-opioid pain management.
The agreement with Premier, Inc. is significant for Pacira as it provides an opportunity to expand the reach of EXPAREL, a key product in its portfolio. By securing special pricing and terms for Premier members, Pacira not only enhances its market penetration but also aligns with its mission of reducing reliance on opioids for pain management. This partnership is likely to be viewed positively by investors, given the potential for increased sales and the strategic alignment with healthcare cost reduction and patient safety improvement.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90